RNA Analytical/Quality Videos

  1. Where Does The mRNA Vaccine Regulatory Paradigm Fall Short For Therapeutics? 5/10/2024

    This Advancing RNA panel of experts sees a couple of important questions those striving to make RNA therapeutics will find themselves confronting when collaborating with regulators.

  2. CMC Innovations Worth Watching In The RNA-LNP Space 12/4/2024

    Sanofi’s Sumit Luthra shares several of the analytical and manufacturing innovations/improvements he’s watching and waiting for that will improve our knowledge of LNP composition, structure, function, and quality.

  3. Fermentation, Analytics, & Quality: Plasmid Production Advancements & Challenges for mRNA Development 4/11/2025

    Advancing RNA Live panelists Tyler Goodwin and April Sena start off our latest discussion on technology innovations in mRNA production by surveying the current manufacturing process for plasmid production, highlighting where they’ve seen advancements and what biotechs need to consider to obtain plasmids of the appropriate quality for mRNA production.

  4. The "Short-Mer" Advantage: The Quality Gains Of siRNA Enzymatic Ligation 3/27/2026

    Is enzymatic ligation merely a "volume play"? In this segment, Advancing RNA Live speakers Claire McCleod and Jill Caswell challenge this belief, explaining the extent at which this paradigm shift also unlocks higher siRNA purity. 

  5. Optimal Tech For Predicting Drug Responses At The Cellular Level 4/1/2025

    Explore how preserving spatial molecular information and leveraging AI-driven spatial-omics can transform treatment prediction, patient stratification, and personalized medicine.

  6. Breaking New Ground: MHRA Embraces A Future With Patient-Specific mRNA 6/24/2025

    In this Advancing RNA clip, panelists Ulrike Jägle and Tiffany Lucas unpack the benefits they see to the MHRA's new guidance on mRNA cancer immunotherapies, including the agency’s support for bioinformatics approaches and its burgeoning framework for developing and justifying a truly personalized medicine.

  7. Why We Still Haven't Solved mRNA Scale-Up 10/15/2025

    While we can make lots of mRNA at a smaller scale, when it comes to scaling up to kg quantities of mRNA, our current batch processes leave a lot to be desired. Together, Stu Sundseth of Tune Therapeutics and Christian Dohmen of Ethris unpack the biggest barriers to scaling IVT to achieve the desired yield and quality of mRNA, offering their take on how the field is innovating to overcome these issues. 

  8. Advancements In LNP CMC: What Are The Current "Known Knowns"? 12/4/2024

    In this Advancing RNA Live clip, Sanofi’s Sumit Luthra highlights the learnings we’ve made to-date about how our processes — both in terms of unit operations and process conditions — inform our LNP composition/heterogeneity.

  9. LBA Vs. LC-MS: Competing Technologies At A Development Crossroad 2/6/2025

    Watch as bioanalytical experts Shane Karnik, MS, and Matt Hartle, Ph.D., explore why many sponsors are reevaluating the use of LBA for large molecule protein analysis in favor of LC-MS.

  10. What's In The Vial?! A [Brief] Meditation On Control Strategy

    Speakers in The State Of The mRNA Supply Chain event tackle an audience member’s question around what matters most: What’s in the vial or what’s in the process?